Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1984 1
1985 3
1986 6
1987 1
1988 3
1989 8
1990 4
1991 13
1992 33
1993 51
1994 101
1995 75
1996 88
1997 65
1998 65
1999 73
2000 74
2001 57
2002 78
2003 70
2004 100
2005 68
2006 74
2007 60
2008 56
2009 72
2010 96
2011 97
2012 77
2013 74
2014 76
2015 85
2016 65
2017 82
2018 91
2019 104
2020 143
2021 177
2022 187
2023 156
2024 56

Text availability

Article attribute

Article type

Publication date

Search Results

2,624 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: 2-chlorooxyadenosine
Page 1
Cladribine (2-chlorodeoxyadenosine).
Beutler E. Beutler E. Lancet. 1992 Oct 17;340(8825):952-6. doi: 10.1016/0140-6736(92)92826-2. Lancet. 1992. PMID: 1357355 Review. No abstract available.
Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.
Chihara D, Arons E, Stetler-Stevenson M, Yuan CM, Wang HW, Zhou H, Raffeld M, Xi L, Steinberg SM, Feurtado J, James L, Wilson W, Braylan RC, Calvo KR, Maric I, Dulau-Florea A, Kreitman RJ. Chihara D, et al. J Clin Oncol. 2020 May 10;38(14):1527-1538. doi: 10.1200/JCO.19.02250. Epub 2020 Feb 28. J Clin Oncol. 2020. PMID: 32109194 Free PMC article. Clinical Trial.
PURPOSE: Single-agent purine analog, usually cladribine, has been the standard first-line therapy of hairy cell leukemia (HCL) for 30 years. ...CONCLUSION: Achieving MRD-free CR of HCL after first-line cladribine is greatly enhanced by concurrent rituximab and less …
PURPOSE: Single-agent purine analog, usually cladribine, has been the standard first-line therapy of hairy cell leukemia (HCL) for 30 …
Efficacy classification of modern therapies in multiple sclerosis.
Samjoo IA, Worthington E, Drudge C, Zhao M, Cameron C, Häring DA, Stoneman D, Klotz L, Adlard N. Samjoo IA, et al. J Comp Eff Res. 2021 Apr;10(6):495-507. doi: 10.2217/cer-2020-0267. Epub 2021 Feb 23. J Comp Eff Res. 2021. PMID: 33620251 Free article.
Background: The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse reduction. We sought to classify newer therapies (cladribine, ocrelizumab, ofatumumab, ozanimod) based on these g …
Background: The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to th …
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group. Giovannoni G, et al. N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089960 Free article. Clinical Trial.
BACKGROUND: Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. ...CONCLUSIONS: Treatment with cladribine tablets significantly reduced relapse rates, the risk of disability progression, and MRI measures of disease activity at 96 …
BACKGROUND: Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. ...CONCLUSIONS: Treatment with …
2-Chlorodeoxyadenosine (Cladribine) preferentially inhibits the biological activity of microglial cells.
Aybar F, Julia Perez M, Silvina Marcora M, Eugenia Samman M, Marrodan M, María Pasquini J, Correale J. Aybar F, et al. Int Immunopharmacol. 2022 Apr;105:108571. doi: 10.1016/j.intimp.2022.108571. Epub 2022 Jan 29. Int Immunopharmacol. 2022. PMID: 35093689
Cladribine (2CdA) is a synthetic chlorinated purine nucleoside analogue which acts as a pro-drug requiring intracellular phosphorylation to be activated. ...
Cladribine (2CdA) is a synthetic chlorinated purine nucleoside analogue which acts as a pro-drug requiring intracellular phosphorylat …
Safety and Monitoring of the Treatment with Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS).
Stamatellos VP, Papazisis G. Stamatellos VP, et al. Curr Rev Clin Exp Pharmacol. 2023;18(1):39-50. doi: 10.2174/2772432817666220412110720. Curr Rev Clin Exp Pharmacol. 2023. PMID: 35418296 Review.
CONCLUSION: Data for oral (Sphingosine 1-phosphate (S1P) receptor modulators, Fumarates, Teriflunomide, Cladribine), injectables (Interferons, Glatiramer acetate, Ofatumumab), and infusion therapies (Natalizumab, Ocrelizumab, Alemtuzumab) are presented....
CONCLUSION: Data for oral (Sphingosine 1-phosphate (S1P) receptor modulators, Fumarates, Teriflunomide, Cladribine), injectables (Int …
2-Chloro-2'-deoxyadenosine.
Delannoy A, Michaux JL. Delannoy A, et al. Acta Clin Belg. 1995;50(4):193-6. doi: 10.1080/17843286.1995.11718446. Acta Clin Belg. 1995. PMID: 7483969 Review. No abstract available.
Cladribine suppresses disease activity in neuromyelitis optica spectrum disorder: a 2-year follow-up study.
Rejdak K, Papuć E. Rejdak K, et al. Eur J Neurol. 2021 Sep;28(9):3167-3172. doi: 10.1111/ene.15012. Epub 2021 Jul 26. Eur J Neurol. 2021. PMID: 34233064
The mean ARR in the 24 months following initiation of cladribine treatment was 0.21 (95% CI 0.08-0.56). The ratio in the rate of events post versus prior cladribine initiation was 0.20 (95% CI 0.07-0.59) and highly significant (p = 0.0073). The EDSS score did not ch …
The mean ARR in the 24 months following initiation of cladribine treatment was 0.21 (95% CI 0.08-0.56). The ratio in the rate of even …
Cladribine: mechanisms and mysteries in multiple sclerosis.
Jacobs BM, Ammoscato F, Giovannoni G, Baker D, Schmierer K. Jacobs BM, et al. J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1266-1271. doi: 10.1136/jnnp-2017-317411. Epub 2018 Jul 10. J Neurol Neurosurg Psychiatry. 2018. PMID: 29991490 Review.
The pharmacology of cladribine explains how it is selectively toxic towards lymphocytes. ...CONCLUSIONS: Cladribine is a safe and effective form of induction therapy for relapsing MS. ...
The pharmacology of cladribine explains how it is selectively toxic towards lymphocytes. ...CONCLUSIONS: Cladribine is a safe …
Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis.
Nabizadeh F, Mohamadi M, Rahmani S, Rajabi R, Afrashteh F, Najdaghi S, Mirmosayyeb O. Nabizadeh F, et al. Neurol Sci. 2023 Sep;44(9):3045-3057. doi: 10.1007/s10072-023-06794-w. Epub 2023 Apr 17. Neurol Sci. 2023. PMID: 37062787 Free PMC article. Review.
The pooled SMD for EDSS before and after treatment was - 0.54 (95%CI: - 1.46, 0.39). Our analysis showed that the PFS after cladribine use is 79% (95%CI 71%, 86%). Also, 58% of patients with MS who received cladribine remained relapse-free (95%CI 31%, 83%). ...Combi …
The pooled SMD for EDSS before and after treatment was - 0.54 (95%CI: - 1.46, 0.39). Our analysis showed that the PFS after cladribine …
2,624 results